News

Cigna’s Coverage Policy includes procedures enabled with OMNI® Surgical System technology as medically necessary and covered.

How AI tools can drive early detection of diabetic eye conditions.

Modern Retina is looking back at the first half of 2023 as we explore the role of AI in the retinal field in anticipation of the changes to come.

Experts in the field weigh in on the perfluorohexyloctane ophthalmic solution, the first and only FDA-approved treatment for DED that directly targets tear evaporation instead of tear formation.

AG-80208 is a novel, first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop to treat the inflammation linked with DED.

Patients with eye disease have an increased risk for developing neurodegenerative disease, and several studies have established a link between neurodegenerative diseases and ophthalmic conditions like glaucoma, diabetic retinopathy, age-related macular degeneration.

Real-world patients often fail to achieve and retain the visual acuity results observed in clinical trials for anti–VEGF-A therapy. Broader therapeutic inhibition of additional angiogenic factors VEGF-C and VEGF-D could change that.

Surgeons seek best IOL match for patients after cataract surgery.

The lenses are designed to correct and prevent myopia in children ages 6 to 14.

New treatment options enhance patient visual outcomes and reduce treatment burdens.

In a presentation at the American Society for Microbiology’s annual meeting, the oral administration of a commercially available probiotic bacterial strain was found to improve dry eye disease in an animal model.

AG-80208 is a novel, first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop to treat the inflammation linked with DED.

Vitrectomy is a tool that can help surgeons curb complications.

Did you miss the 2023 European Society of Ophthalmology congress? Don't worry – you can catch up with our video coverage.

In April, the FDA approved an update to the TEPEZZA indication language, specifying its use in all patients with TED regardless of TED activity or duration. Horizon Therapeutics presented its data at the Endocrine Society's 2023 annual meeting in Chicago.

Antimicrobial resistance is resistance to multiple classes of antibiotics, which makes it extremely challenging to treat infections caused by such organisms.

Artificial intelligence (AI) is going to be highly instrumental in patient care in all medical specialties and will be highly relevant in eye care.

Antimicrobial resistance is resistance to multiple classes of antibiotics, which makes it extremely challenging to treat infections caused by such organisms.

Artificial intelligence (AI) is going to be highly instrumental in patient care in all medical specialties and will be highly relevant in eye care.

EyeBio has begun the dosing of the first participants in its Phase 1b/2 AMARONE clinical trial for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).

The clinical trial successfully achieved statistical significance for the primary endpoint and all secondary endpoints.

The study results could help lead to improved understanding of glaucoma and new therapies.

Dr Ala Moshiri provides an overview of current treatment options for diabetic macular oedema.

Ala Moshiri, MD, PhD, provides an overview of current treatment options for diabetic macular edema.

On this episode of the NeuroOp Guru video blog, Andy Lee, MD, and Drew Carey, MD, discuss the use of fluoxetine in patients with visual field loss after suffering a stroke.

The MERIT study found that intraocular corticosteroid treatment remains the most effective therapy for uveitis-related macular edema, and vision gains in participants who received the corticosteroid treatment were very promising.